164 related articles for article (PubMed ID: 36065389)
1. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study.
Wang G; Si T; Rieckmann A; Ma J; Christensen MC
Neuropsychiatr Dis Treat; 2024; 20():1211-1223. PubMed ID: 38863483
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study.
De Filippis S; Pugliese A; Christensen MC; Rosso G; Di Nicola M; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1665-1677. PubMed ID: 35971416
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study.
Mattingly G; Brunner E; Chrones L; Lawrence DF; Simonsen K; Ren H
Front Psychiatry; 2022; 13():977560. PubMed ID: 36683990
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
[TBL] [Abstract][Full Text] [Related]
8. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
Papalexi E; Galanopoulos A; Kontis D; Markopoulou M; Balta G; Karavelas E; Panagiotidis P; Vlachos T; Ettrup A
BMC Psychiatry; 2022 Aug; 22(1):548. PubMed ID: 35962369
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
[TBL] [Abstract][Full Text] [Related]
13. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
Cumbo E; Adair M; Åstrom DO; Christensen MC
Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
[TBL] [Abstract][Full Text] [Related]
15. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
16. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
McCue M; Sarkey S; Eramo A; François C; Parikh SV
BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
18. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
Yang YK; Chen CS; Tsai CF; Chang CM; Lai TJ; Lee CT; Lin CC; Lan TH; Herr KJ
Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
[TBL] [Abstract][Full Text] [Related]
19. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
[No Abstract] [Full Text] [Related]
20. Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea.
Moon SW; Kim JW; Kim DH; Lee KY; Reines EH; Lee M; Park YJ
Front Psychiatry; 2023; 14():1075939. PubMed ID: 36937717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
